Navigation Links
Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement
Date:9/28/2007

CHARLOTTESVILLE, Va., Sept. 28 /PRNewswire/ -- Diffusion Pharmaceuticals LLC, a clinical-stage drug development company commercializing first-in-class drugs utilizing a novel mechanism of action that enhances oxygen diffusion, today announced the results of a Phase I safety trial of its lead drug candidate, trans sodium crocetinate (TSC). In addition, the company announced the completion of a $4.5 million private placement, the proceeds of which will support the company's overall growth and advance TSC into Phase II clinical trials in early 2008.

Diffusion Pharmaceuticals' initial safety study was a double-blind, placebo-controlled, dose-escalation study designed to evaluate the tolerability and pharmacokinetics of a single intravenous bolus injection of TSC in healthy human subjects. The study demonstrated that TSC is very well-tolerated, raising no significant clinical issues in humans at doses significantly higher than the doses to be used in upcoming clinical trials in patients.

"Successful completion of this study is a key milestone in the clinical development of TSC and significantly advances our lead product candidate toward commercialization," said David G. Kalergis, Chief Executive Officer of Diffusion Pharmaceuticals. "The results of our Phase I trial and recent preclinical studies, coupled with completion of the private placement, will enable us to move quickly into Phase II proof-of-concept studies with TSC in two diverse patient populations -- peripheral vascular disease and cancerous brain tumors -- both of which exhibit oxygen deprivation at the cellular level," said Kalergis.

The company's next clinical study will examine the safety and effects of TSC on oxygenation levels of cancerous tumor tissue in primary brain tumor patients who have glioblastoma multiforme (GBM) and will be undergoing a surgical procedure for tumor biopsy and/or tumor resection. Further trials in GBM patients will examine the safety and effects of TSC, including impact on patient survival, when combined with radiation therapy. These clinical trials will be sponsored by Diffusion Pharmaceuticals LLC, and conducted in collaboration with The Johns Hopkins University School of Medicine and the New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System (CNS) Consortium.

Dr. Stuart Grossman, Director of Clinical and Laboratory Neuro-Oncology Programs at Johns Hopkins and project leader for NABTT said, "TSC's novel mechanism of action provides a whole new approach to enhancing radiation therapy. We are excited by its prospects and intend to start clinical trials in patients with primary brain tumors as soon as possible."

In addition, the company is planning a clinical trial in peripheral vascular disease patients suffering from intermittent claudication (i.e., intense leg pain while walking) to evaluate the effect of TSC on tissue oxygenation in these patients using a standardized treadmill test. Site selection for this study is currently underway.

Diffusion Pharmaceuticals' pipeline of first-in-class small molecules uses a novel mechanism of action allowing more oxygen to reach oxygen-deprived (hypoxic) tissues in the body. The diffusion of oxygen through blood plasma and into tissue is a critical step in delivering oxygen to hypoxic tissue; Diffusion Pharmaceuticals' drugs affect this process. In preclinical studies, TSC has been shown to increases the rate of oxygen diffusion by about 30 percent. TSC has been shown in animal models to increase the diffusion of oxygen into hypoxic cancerous tumor tissue, making the cancer more susceptible to radiation therapy and increasing survival. In addition, animals suffering severe blood loss have a higher rate of survival if treated with TSC.

The ability to enhance oxygen diffusion into hypoxic tissue represents a transformative technology, with potentially far-ranging implications for human health and the practice of medicine. Diffusion Pharmaceuticals' family of drugs can potentially be used in a broad range of conditions such as cardiovascular disease, cancer, respiratory disorders and other serious or life-threatening medical conditions. If approved for marketing by the U.S. Food and Drug Administration (FDA), the patient population for successful Diffusion-owned, patent-protected molecules such as TSC could be in the millions.

To date, Diffusion Pharmaceuticals has raised $10.2 million in private equity and has received $2.6 million in government research and development funding from the Office of Naval Research (ONR), bringing the company's total funding to $12.8 million.

About Diffusion Pharmaceuticals LLC

Diffusion Pharmaceuticals LLC is a clinical-stage drug-development company commercializing a family of first-in-class drug candidates to treat serious or life-threatening medical conditions. These proprietary small molecules use a novel method of action to enhance oxygen diffusion to oxygen deprived (hypoxic) tissue. Potential clinical applications include critical care uses such as trauma, hemorrhage, stroke and heart attack, as well as chronic conditions such as cardiovascular disease, respiratory disorders and peripheral vascular disease. Additionally, enhanced diffusion of oxygen into hypoxic tissue also has an important application in oncology by improving the efficacy of radiation therapy in cancerous tumors. The Company's first Phase I clinical trial for its lead molecule, trans sodium crocetinate (TSC), shows the drug is well-tolerated in healthy human subjects at doses significantly higher than the estimated efficacious human dose. Clinical trials will begin in early 2008 in cancer patients undergoing radiation therapy and in peripheral vascular disease patients suffering from intermittent claudication. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit http://www.diffusionpharma.com.


'/>"/>
SOURCE Diffusion Pharmaceuticals LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... , Sept. 18, 2017  PMD Healthcare of ... Pharmacy of Kalamazoo, Mich. , have ... service that expedites and streamlines patient and provider access ... 2.0, and wellness management services.  ... used to measure lung function for a variety of ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
(Date:9/9/2017)... -- ... Washington DC ... 12 th – Monday, September 18 th .The Brain Tumor Foundation ... scans to the public.Where:  BTF,s Mobile MRI Unit ... Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the Road to Early ...
Breaking Medicine Technology: